Tiglyiglycine (TG), an intermediate product of the catabolism of isoleucine, is increased in the urine of patients with p-ketothiolase deficiency or with disorders of propionate metabolism. it is also implicated as a useful diagnostic marker in disorders of the respiratory chain. We present a method for the synthesis of TG and tiglyl[13C,15N)glycineand the development of a stable isotope dilution mass spectrometric assay for TG. We compare data from controls with that from subjects with p-ketothiolase deficiency and propionyl-CoA carboxylase deficiency, and with six patients with enzyme-confirmed disorders of the respiratory chain. TG was increased in the urine from all of the patient groups. The increased TG excretion did not persist in one patient with a respiratory chain defect, which suggests that, in some patients, multiple sample analysis may be necessary to identify a respiratory chain defect. This is the first urinary compound to be implicated as a potential marker of disorders of the respiratory chain. (Fig. 1) . Recently, we identified increased urinary TG in patients with disorders of complex I of the mitochondrial respiratory chain (4). It would be very useful to have a metabolic marker for complex I deficienciy and other disorders of the respiratory chain, which are a very difficult group of disorders to diagnose. (Fig. 2) .
Tiglyiglycine (TG), an intermediate product of the catabolism of isoleucine, is increased in the urine of patients with p-ketothiolase deficiency or with disorders of propionate metabolism. it is also implicated as a useful diagnostic marker in disorders of the respiratory chain. We present a method for the synthesis of TG and tiglyl[13C,15N)glycineand the development of a stable isotope dilution mass spectrometric assay for TG. We compare data from controls with that from subjects with p-ketothiolase deficiency and propionyl-CoA carboxylase deficiency, and with six patients with enzyme-confirmed disorders of the respiratory chain. TG was increased in the urine from all of the patient groups. The increased TG excretion did not persist in one patient with a respiratory chain defect, which suggests that, in some patients, multiple sample analysis may be necessary to identify a respiratory chain defect. This is the first urinary compound to be implicated as a potential marker of disorders of the respiratory chain. Fig. 1) . Recently, we identified increased urinary TG in patients with disorders of complex I of the mitochondrial respiratory chain (4). It would be very useful to have a metabolic marker for complex I deficienciy and other disorders of the respiratory chain, which are a very difficult group of disorders to diagnose. SUCCinYI-COA The pooled organic fractions were evaporated to dryness under a steady stream of nitrogen gas at 37#{176}C. Trimethylsilyl (TMS) derivatives were formed by adding 100 L of bis(trimethylsilyl)trifluoroacetamide containing 10 mLIL trimethyichiorosilane (Supebco, Bellefonte, PA) and heating to 80#{176}C for 30 mm. We injected 2-zL aliquots onto a 25 m x 0.2 mm (i.d.) HP5 (cross-linked 5% phenylmethyl silicone) capillary column, fitted into a HP 5970A Mass Selective Detector (both from Hewlett-Packard, Palo Alto, CA). The injector temperature was 260#{176}C, the detector temperature 285#{176}C, and the oven temperature 80#{176}C, programmed to increase at 4#{176}C! mm to 275#{176}C, where it remained for 15 mm. Injection was in the split mode (-10:1), and detection was in the electron impact mode, scanning the ions at mlz 50 to 500 amu.
Both TG and ['3C,"N]TG produced a single peak under these conditions, corresponding to the mono-TMS derivatives only (Fig. 3) . The spectrum for TG is identical to that previously published by Goodman 
Analysis for TG in Urine Samples
Urines were obtained from a series of 44 controls. This group included urines from normal infants and children (ages 3 months to 16 years, n = 21), normal adults (n = 6), normal newborns (n = 5), and newborns with evidence of asphyxia acidemia (n = 2); postmortem urine demonstrating lactic acidemia (n = 2); urines from fasting ketotic infants (ages 3 months to 1 year, n = 6); and urines from two patients with medium-chain acyl-CoA dehydrogenase deficiency (both homozygeous for the A985G mutation).
We also obtained urines (disease group) from a patient with classical propionic acidemia (four urine samples) and from a patient with atypical The patients with respiratorychain defects correspond to the patients in Table   1 for the calibration curve. The selected ion mode was used, as described above.
Results

Linearity
and detection limits. The calibration curve, based on both urine and aqueous solutions, was linear to about 100 moI/L (Fig. 4) . At greater concentrations there was a lack of linearity, which we attribute to increasing amounts of the natural abundance of the m!z 172 ion. We recommend that appropriate dilutions be made in unknown urines with TG values >100 1mol/L. The signal-to-noise ratio at 0.1 tmolJL was -10:1. Thus, we consider the detection limit for a 0.5-mL sample to be 0.1 .tmolJL.
Urine TG concentrations in controls and disease patients. Fig. 5 shows the values obtained for 44 control subjects: mean value 1.36 ± 1.12 mmol/mol creatinine; range 0.14-3.8.
One sample analyzed on five separate occasions gave a mean result of 0.74 (SD 0.08) mmoll mol, for a CV of 11%. As shown in Fig. 5 and Table 1, TG  concentrations were consistently greater than the controls' in the patients with Pearson syndrome or propi- Control range 0.14-3.8
Results for samples collected during patients' illness; results for samples collected when patients were well are indicated in parentheses.
onic acidemia and in the patient with 2-MAA thiolase deficiency. The concentrations in the four other patients with respiratory chain defects were also increased, but not consistently so in one. The control urinary range of TG varied from 0.14 to 3.84 mmollmol creatinine, which is within the estimated concentration range of <2.0 mmol/mol provided by Sweetman (14) but lower than the range recently suggested by Guneral and Bachman (15). Neither previous estimate was based on the use of stable isotopes, and both are potentially inaccurate. Our inclusion of ketotic samples and samples from patients with secondary lactic acidemia in the "normal" range study was to control for the ketosis in disorders of isoleucine metabolism and the primary lactic acidemia found in respiratory chain defects. A measurable peak of TG was detectable in all samples analyzed, confirming that the sensitivity of the assay was adequate for use in such studies.
Increased TG excretion was detected in a patient with PCC deficiency in samples collected when clinically well and also during metabolic decompensation, when the amount excreted was even higher. The modest increase seen in the patient in 2-MAA thiolase deficiency is in keeping with previous experience in this atypical patient, who has high residual enzyme activity and appears to fall into a unique complementation group (10). Previous estimates of TG excretion in complete 2-MAAthiolase deficiency range up to 1000 mol/L (14). Particularly interesting were the patients with Pearson syndrome, who had consistently high excretion of TG even though neither patient was metabolically stressed. Urinary TG measurement, therefore, should aid the diagnosis of this condition. The mechanism of the TG increase in all patients with abnormalities of the respiratory chain is probably through secondary inhibition of 2-methyl-3-hydroxybutyryl-CoA dehydrogenase, an NAB Frequiring dehydrogenase (Fig. 1) We conclude that there is great potential for use of this method to discriminate between patients with primary respiratory chain abnormalities and those with secondary lactic acidemia, a discrimination that is at present difficult to achieve.
